I’ve got $1000.00 to dump in the market today. Give me your plays, but don’t be boring.
ATNF under $200 mil market cap, founders (Sir Marc Feldman and Jim Woody) discovered anti-TNF science and sold their bio (Google Centocor biotech, Remicade drug) to JNJ for $4.9 billion. Anti-TNF has since been the largest selling drug class in the world every year since 2012 (Google Humira #1 in the world over $20 billion annual sales, Enbrel #3 with over $8 billion, Remicade #10 nearly $5 billion). They have phase 2b/3 trial results coming in Q4 for first drug in the pipeline for Dupuytren's disease. These trials and the pipeline also include 3 other anti-TNF indications and are all done at Oxford (which is obviously a top 5 university in the world), where they aren't making anything new, just finding new indications for the existing FDA approved drugs.
This is 3 bio's merged to one and that is #1. Another is SCA's (synthetic cannabinoid analogs) where the goal is to replace anti-TNF/opioids completely. Raphael Mechoulam (The Godfather of Cannabis) who discovered THC/CBD and the human body's endocannabinoid system, has been developing SCA's for years and Marc Feldman who discovered anti-TNF science screened Mecholam's best 20 SCA's to pick out his favorite for inflammation. This will be a pure synthetic canniboid that is >99.5% CBD.
The third bio is led by a couple guys at Stanford (also a top 5 university in the world), who have sold drugs for $2.85 billion and $5.4 billion. If you can't math, 4.9 + 5.4 + 2.85 means they have already sold nearly $14 billion worth of drugs, and as I mentioned, market cap is under $200 mil right now. Holding long and strong until they get bought out or become the next Big Pharma
.